Compare EVAX & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | RDI |
|---|---|---|
| Founded | 2008 | 1937 |
| Country | Denmark | United States |
| Employees | N/A | 2005 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 25.7M |
| IPO Year | 2020 | N/A |
| Metric | EVAX | RDI |
|---|---|---|
| Price | $4.35 | $1.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 30.2K | 17.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.25 |
| Revenue Next Year | $328.20 | $4.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.94 |
| 52 Week High | $12.15 | $1.65 |
| Indicator | EVAX | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 44.40 |
| Support Level | $2.64 | $0.99 |
| Resistance Level | $4.62 | $1.16 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 30.71 | 12.12 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.